{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-035943","form_type":"8-K","ticker":"ITRMF","cik":"0001659323","company_name":"Iterum Therapeutics plc","filed_at":"2025-03-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:04.343635+00:00","generated_at":"2026-05-25T01:36:21.998052+00:00","sec_items":["5.02","8.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.4,"confidence":"high","headline":"Iterum Therapeutics appoints Joseph Whalen to board; David Kelly named Chairman","bullets":["Joseph J. Whalen appointed as Class III director effective March 10, 2025; term expires at 2027 AGM.","Whalen joins Audit and Compensation Committees; receives annual cash retainers of $35,000 (board), $7,500 (audit), $6,000 (compensation).","David Kelly appointed Chairman of the Board effective March 10, 2025, after Ronald Hunt resigned on February 14, 2025.","Whalen's appointment restores Audit Committee to three independent members, regaining Nasdaq Listing Rule 5605(c)(2)(A) compliance."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-035943","json":"https://secwatch.observer/filing/0000950170-25-035943.json","markdown":"https://secwatch.observer/filing/0000950170-25-035943.md","text":"https://secwatch.observer/filing/0000950170-25-035943.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1659323/000095017025035943/0000950170-25-035943-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1659323/000095017025035943/itrm-20250307.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-25T01:36:21.998052+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"aca580e0fc","claim":"Joseph J. Whalen was appointed as Class III Director at Iterum Therapeutics plc.","evidence_excerpt":"approved the appointment of Joseph J. Whalen as a member of the Board, effective as of March 10, 2025.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1659323/000095017025035943/0000950170-25-035943-index.htm","confidence":0.95},{"claim_id":"dd3bddcdb1","claim":"David Kelly was appointed as Chairman of the Board at Iterum Therapeutics plc.","evidence_excerpt":"the Board also appointed David Kelly, an existing director of the Board, as Chairman of the Board, effective as of March 10, 2025.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1659323/000095017025035943/0000950170-25-035943-index.htm","confidence":0.95}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}